Sequester May Further Depress AmerisourceBergen’s Oncology Drug Sales
Executive Summary
Wholesalers AmerisourceBergen and McKesson discuss the potential impact of the federal budget sequester and the resulting cut to Part B drug reimbursement on oncology drug sales.
You may also be interested in...
Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs
A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.